NCT02900183View on ClinicalTrials.gov

Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
DRUG

ARC-AAT Injection

RNA interference (RNAi)-based, liver-targeted therapeutic

Trial Locations (4)

27100

IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia

M5T3A9

Inspiration Research Limited, Toronto

Unknown

Beaumont Hospital, Dublin

SE-205 02

Skane University Hospital, Department of Gastroenterology, Malmo

Sponsors
All Listed Sponsors
lead

Arrowhead Pharmaceuticals

INDUSTRY